Hosted on MSN18d
Mallinckrodt and Endo sign $6.7bn merger deal
Endo’s portfolio includes Xiaflex (collagenase clostridium histolyticum) for Dupuytren’s contracture and Peyronie’s disease, as well as a range of generics and sterile injectables. As part of the ...
Hosted on MSN17d
Endo, Inc. Shares Positive Data on XIAFLEX Treatment for Peyronie’s Disease
MALVERN, PA — Endo, Inc. (OTCQX: NDOI) revealed new insights from a post hoc data analysis of its Phase 3 clinical trial of XIAFLEX® (collagenase clostridium histolyticum, or CCH) for the ...
Endo Launches Spatial Computing Simulator to Create a Fully Immersive Learning Environment for Hand Specialists
Endo, Inc. (OTCQX: NDOI) announced today the launch of a first-of-its-kind initiative for a pharmaceutical company: the ...
Morningstar1mon
Endo Launches "Steve's Journey," the First Branded Dupuytren's Contracture Commercial for XIAFLEX® (collagenase clostridium histolyticum)
The campaign, featuring a real Dupuytren's contracture patient, encourages patients to consult a hand specialist and ask about XIAFLEX® (collagenase clostridium histolyticum), the only FDA ...
Morningstar8d
Endo Presents Dupuytren Contracture Data at the IFSSH and IFSHT Triennial Congress
MALVERN, Pa., March 24, 2025 /PRNewswire/ -- Endo, Inc. (OTCQX: NDOI) announced today that data related to the use of XIAFLEX® (collagenase clostridium histolyticum, or CCH) for the treatment of ...
Longview News-Journal20d
Endo Announces Peyronie's Disease Presentation at the Annual Meeting of the Southeastern Section of the American Urological Association
March 12, 2025 /PRNewswire/ -- Endo, Inc. (OTCQX: NDOI) announced today that a post hoc data analysis of a Phase 3 clinical trial of XIAFLEX ® (collagenase clostridium histolyticum, or CCH ...
Endo Presents Dupuytren Contracture Data at the IFSSH and IFSHT Triennial Congress
Endo, Inc. (OTCQX: NDOI) announced today that data related to the use of XIAFLEX® (collagenase clostridium histolyticum, or ...
Endo Announces Peyronie's Disease Presentation at the Annual Meeting of the Southeastern Section of the American Urological Association
Endo, Inc. (OTCQX: NDOI) announced today that a post hoc data analysis of a Phase 3 clinical trial of XIAFLEX® (collagenase clostridium histolyticum, or CCH) in patients with Peyronie's disease (PD) ...